Journal
SURGICAL CLINICS OF NORTH AMERICA
Volume 88, Issue 3, Pages 615-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.suc.2008.03.008
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA006973] Funding Source: Medline
Ask authors/readers for more resources
Soft tissue sarcomas in children are rare. Approximately 850 to 900 children and adolescents are diagnosed each year with rhabdomyosarcoma (RMS) or a non-RMS soft tissue sarcoma (NRSTS). RMS is more common in children 14 years old and younger and NRSTS in adolescents and young adults. Infants get NRSTS, but their tumors constitute a distinctive set of histologies. Surgery is a major therapeutic modality and radiation plays a role. RMS is treated with adjuvant chemotherapy, whereas chemotherapy is reserved for the NRSTS that are high grade or unresectable. This review discusses the etiology, biology, and treatment of pediatric soft tissue sarcomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
